as 10-28-2024 4:00pm EST
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
Founded: | 2010 | Country: | United States |
Employees: | N/A | City: | REDWOOD CITY |
Market Cap: | 100.9M | IPO Year: | 2014 |
Target Price: | $7.13 | AVG Volume (30 days): | 2.7M |
Analyst Decision: | Buy | Number of Analysts: | 5 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.27 | EPS Growth: | N/A |
52 Week Low/High: | $0.73 - $3.73 | Next Earning Date: | 11-08-2024 |
Revenue: | $308,134,000 | Revenue Growth: | 69.37% |
Revenue Growth (this year): | 5.18% | Revenue Growth (next year): | 16.86% |
CHRS Breaking Stock News: Dive into CHRS Ticker-Specific Updates for Smart Investing
GuruFocus.com
20 days ago
Insider Monkey
a month ago
Insider Monkey
a month ago
Simply Wall St.
a month ago
MT Newswires
2 months ago
MT Newswires
2 months ago
Simply Wall St.
3 months ago
Zacks
3 months ago
The information presented on this page, "CHRS Coherus BioSciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.